Fluoxetine for Visual Recovery After Ischemic Stroke

• Status: Terminated
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether fluoxetine, a selective serotonin reuptake inhibitor commonly used for depression, enhances visual recovery after an acute ischemic stroke.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bogachan Sahin
• Treatments: Fluoxetine; Serotonin Uptake Inhibitors

Criteria

Inclusion Criteria:

• MRI-confirmed acute ischemic stroke resulting in an isolated homonymous visual field loss.

Exclusion Criteria:

• Known hypersensitivity to fluoxetine or other selective serotonin reuptake inhibitors

• National Institutes of Health Stroke Scale score greater than 5

• Premorbid modified Rankin Scale score greater than 2

• Premorbid monocular or binocular visual field deficits

• Premorbid retinopathy or optic neuropathy

• Premorbid depression

• History of cognitive impairment, dementia, or neurodegenerative disorder

• History of seizure disorder

• History of mania or hypomania

• History of hyponatremia

• History of angle-closure glaucoma or elevated intraocular pressure

• Current alcohol abuse or impaired liver function

• Current use of an antidepressant medication

• Current use of a medication likely to have an adverse interaction with fluoxetine

• Current use of a medication likely to impair post-stroke recovery

• Contraindication to MRI

• Pregnancy or lactation

• Hemorrhagic transformation of the index stroke, resulting in mass effect

• Enrollment in another clinical trial at the time of the index stroke